LYNDA ARTUSIO: Open Payments
NPI 1841363702 · FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$443 in 21 payments from 7 companies in 2025. Trend: 2023 $457 · 2024 $152 · 2025 $443
Food & beverage: $414Education: $29
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $166 |
| Axsome Therapeutics, Inc. | 3 | $146 |
| Otsuka America Pharmaceutical, Inc. | 3 | $46 |
| Novo Nordisk Inc | 1 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Alkermes, Inc. | 1 | $21 |
| TOLMAR, INC. | 1 | $18 |
Products named: INGREZZA, Auvelity, REXULTI, Ozempic, CAPLYTA, ARISTADA, JATENZO.
Industry payments across MD — which companies pay providers there.
